IBDEI169 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20984,0)
 ;;=704.1^^133^1308^17
 ;;^UTILITY(U,$J,358.3,20984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20984,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,20984,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,20984,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,20985,0)
 ;;=251.2^^133^1308^29
 ;;^UTILITY(U,$J,358.3,20985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20985,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,20985,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,20985,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,20986,0)
 ;;=257.2^^133^1308^30
 ;;^UTILITY(U,$J,358.3,20986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20986,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,20986,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,20986,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,20987,0)
 ;;=253.2^^133^1308^33
 ;;^UTILITY(U,$J,358.3,20987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20987,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,20987,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,20987,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,20988,0)
 ;;=733.00^^133^1308^43
 ;;^UTILITY(U,$J,358.3,20988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20988,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,20988,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,20988,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,20989,0)
 ;;=278.00^^133^1308^40
 ;;^UTILITY(U,$J,358.3,20989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20989,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,20989,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,20989,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,20990,0)
 ;;=278.01^^133^1308^39
 ;;^UTILITY(U,$J,358.3,20990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20990,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,20990,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,20990,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,20991,0)
 ;;=250.80^^133^1308^4
 ;;^UTILITY(U,$J,358.3,20991,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20991,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,20991,1,5,0)
 ;;=5^DM Type II w/ LE Ulcer
 ;;^UTILITY(U,$J,358.3,20991,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,20992,0)
 ;;=250.00^^133^1308^9
 ;;^UTILITY(U,$J,358.3,20992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20992,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,20992,1,5,0)
 ;;=5^DM Type II w/o Complications
 ;;^UTILITY(U,$J,358.3,20992,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,20993,0)
 ;;=250.40^^133^1308^5
 ;;^UTILITY(U,$J,358.3,20993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20993,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,20993,1,5,0)
 ;;=5^DM Type II w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,20993,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,20994,0)
 ;;=250.50^^133^1308^7
 ;;^UTILITY(U,$J,358.3,20994,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20994,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,20994,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,20994,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,20995,0)
 ;;=250.60^^133^1308^6
 ;;^UTILITY(U,$J,358.3,20995,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20995,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,20995,1,5,0)
 ;;=5^DM Type II w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,20995,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,20996,0)
 ;;=250.70^^133^1308^8
 ;;^UTILITY(U,$J,358.3,20996,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20996,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,20996,1,5,0)
 ;;=5^DM Type II w/ Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,20996,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,20997,0)
 ;;=250.01^^133^1308^3
 ;;^UTILITY(U,$J,358.3,20997,1,0)
 ;;=^358.31IA^5^2
